Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18288691 | 0.92 | HCAR2 (0.45) | HCAR2KEAP1NFE2L2TDP1ESR1 | |
| SCHEMBL18288652 | 0.92 | HCAR2 (0.45) | HCAR2KEAP1NFE2L2TDP1ESR1 | |
| SCHEMBL2115988 | 0.85 | HCAR2 (0.59) | HCAR2KEAP1NFE2L2KDM4EMAPT | |
| SCHEMBL2115986 | 0.85 | HCAR2 (0.59) | HCAR2KEAP1NFE2L2KDM4EMAPT | |
| SCHEMBL23241118 | 0.80 | ALDH1A1 (0.45) | HCAR2KEAP1NFE2L2GFPT1KDM4E | |
| SCHEMBL2609717 | 0.80 | ALDH1A1 (0.45) | HCAR2KEAP1NFE2L2GFPT1KDM4E | |
| SCHEMBL17777292 | 0.80 | ALDH1A1 (0.45) | HCAR2KEAP1NFE2L2GFPT1KDM4E | |
| SCHEMBL2114191 | 0.78 | HCAR2 (0.56) | HCAR2KEAP1NFE2L2GFPT1KDM4E | |
| SCHEMBL2114189 | 0.78 | HCAR2 (0.56) | HCAR2KEAP1NFE2L2GFPT1KDM4E | |
| SCHEMBL19760891 | 0.77 | HCAR2 (0.39) | HCAR2KEAP1NFE2L2GFPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11246850-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| US-11129806-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11007166-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11007167-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10959972-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20210023040-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2021-01-28 | — | — | US | disclosed |
| US-20200345679-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2020-11-05 | — | — | US | disclosed |
| US-20190125710-A1 | Methods of Treating Multiple Sclerosis | BIOGEN MA INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20170368013-A1 | Methods of Treating Multiple Sclerosis | BIOGEN MA INC. | 2017-12-28 | — | — | US | disclosed |
| US-8778991-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129806-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | HCAR2 1264/4885KEAP1 1718/4885NFE2L2 2166/4885 |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | HCAR2 70/4885KEAP1 2571/4885NFE2L2 2133/4885 |
| US-20190125710-A1 | Methods of Treating Multiple Sclerosis | FAH, FH, PML | HCAR2 1264/4885KEAP1 1718/4885NFE2L2 2166/4885 |
| US-20210023040-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | HCAR2 1264/4885KEAP1 1718/4885NFE2L2 2166/4885 |
| US-11007167-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | HCAR2 1264/4885KEAP1 1718/4885NFE2L2 2166/4885 |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | HCAR2 68/4885KEAP1 2596/4885NFE2L2 2036/4885 |
| US-11007166-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | HCAR2 1264/4885KEAP1 1718/4885NFE2L2 2166/4885 |
| US-20170368013-A1 | Methods of Treating Multiple Sclerosis | FAH, FH, PML | HCAR2 1264/4885KEAP1 1718/4885NFE2L2 2166/4885 |
| US-11246850-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | HCAR2 1264/4885KEAP1 1718/4885NFE2L2 2166/4885 |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | HCAR2 1264/4885KEAP1 1718/4885NFE2L2 2166/4885 |
| US-10959972-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | HCAR2 1264/4885KEAP1 1718/4885NFE2L2 2166/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | HCAR2 70/4885KEAP1 2571/4885NFE2L2 2133/4885 |
| US-20200345679-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | HCAR2 1264/4885KEAP1 1718/4885NFE2L2 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.